Skip to content

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061793
Enrollment
Unknown
Registered
2022-07-02
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma complicated with portal vein tumor thrombus

Interventions

Observation group:None

Sponsors

The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were patients with 1. HCC with ePVTT as defined in the subsequent section of this article; 2. age over 18 years; 3. unresectable HCC as assessed by experienced liver surgeons; 4. good general status and liver function of Pugh-Child A or B.

Exclusion criteria

Exclusion criteria: The exclusion criteria were patients with 1. contraindications to atezo/bev or IMRT; 2. prior HCC treatment; 3. history of other cancers; 4. pregnancy. Patients with extrahepatic spread of HCC was not a contraindication of this study.

Design outcomes

Secondary

MeasureTime frame
Progression-free survival;Overall survival;Incidence of adverse events;

Primary

MeasureTime frame
Objective response rate;

Countries

China

Contacts

Public ContactKang Wang
wangkang_md@aliyun.com+86 18817302388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026